Lineage Cell Therapeutics (XTAE:LCTX) Accounts Receivable : ₪0.29 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Lineage Cell Therapeutics Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Lineage Cell Therapeutics's accounts receivables for the quarter that ended in Mar. 2024 was ₪0.29 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Lineage Cell Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 was 4.86.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Lineage Cell Therapeutics's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was ₪0.15.

Lineage Cell Therapeutics Accounts Receivable Historical Data

The historical data trend for Lineage Cell Therapeutics's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lineage Cell Therapeutics Accounts Receivable Chart

Lineage Cell Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

Get a 7-Day Free Trial

1.18

0.02

188.99

1.10

2.77

Lineage Cell Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Receivable	Get a 7-Day Free Trial															0.76	1.65	1.61	2.77	0.29

Lineage Cell Therapeutics Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Lineage Cell Therapeutics Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Lineage Cell Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.286	/	5.368	*	91
=	4.86

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Lineage Cell Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Lineage Cell Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(162.152	+	0.75 * 0.286	+	0.5 * 0	-	139.373
-	0	-	-5.249)	/	188.754
=	0.15

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Lineage Cell Therapeutics Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Lineage Cell Therapeutics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Lineage Cell Therapeutics (XTAE:LCTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lineage Cell Therapeutics Inc (XTAE:LCTX) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

LCTX:USA BT3:Germany

Address

2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008

Website

https://www.lineagecell.com

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cell transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.